Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: Individual patient data and aggregate data meta-analyses

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Khan, Faiz Ahmad ^a,b   Salim, M A Hamid ^c   du Cros, Philipp ^d   Casas, Esther C ^d   Khamraev, Atajan ^e,f   Sikhondze, Welile ^g   Benedetti, Andrea ^a,b,g   Bastos, Mayara ^a,h   Lan, Zhiyi ^a,g   Jaramillo, Ernesto ⁱ   Falzon, Dennis ⁱ   Menzies, Dick ^a,b,g  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c National Immunization Program of Bangladesh   (Bangladesh)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e TASHKENT PEDIATRIC MEDICAL INSTITUTE   (Uzbekistan)

^f Ministry of Health   (Swaziland)

^g MCGILL UNIVERSITY   (Canada)

^h STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; CONFIDENCE INTERVAL; CONSULTATION; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EYE DISEASE; FLUOROQUINOLONE RESISTANCE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; LIVER DISEASE; MEDICAL RECORD; MENTAL DISEASE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; ODDS RATIO; OTOTOXICITY; RELAPSE; RIFAMPICIN RESISTANCE; RISK FACTOR; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; ADULT; DRUG EFFECT; FEMALE; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDIES AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85034806931     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00061-2017     Document Type: Article

References (21)

1. WHO. Global Tuberculosis Report. Geneva, World Health Organization, 2016.
2. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
3. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis - 2011 update. Geneva, World Health Organization, 2011.
4. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
5. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
6. Van Deun A, Maug AK, Hamid Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
7. Aung KJ, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
8. WHO. WHO Treatment Guidelines for Drug-Resistant Tuberculosis - 2016 update. Geneva, World Health Organization, 2016.
9. Bastos M, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1600803.
10. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008; 61: 41-51.
11. Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
12. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
13. WHO. WHO Treatment Guidelines for Drug-Resistant Tuberculosis - 2016 update. Online appendix. http://apps.who.int/iris/bitstream/10665/250125/5/9789241549639-webannexes-eng.pdf?ua=12016 Date last accessed: March 22, 2017.
14. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.
15. Sotgiu G, Tiberi S, D'Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387: 2486-2487.
16. Varaine F, Guglielmetti L, Huerga H, et al. Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations. Am J Respir Crit Care Med 2016; 194: 1028-1029.
17. Cegielski JP, Kurbatova E, van der Walt M, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 2016; 62: 418-430.
18. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
19. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
20. Franke MF, Becerra MC, Tierney DB, et al. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc 2015; 12: 674-679.
21. WHO. Active Tuberculosis Drug-Safety Monitoring and Management (aDSM). Framework for Implementation. Geneva, World Health Organization, 2015.